Birinapant
- Generic Name
- Birinapant
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C42H56F2N8O6
- CAS Number
- 1260251-31-7
- Unique Ingredient Identifier
- 6O4Z07B57R
- Background
Birinapant has been investigated for the treatment of Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML).
- Associated Conditions
- -
- Associated Therapies
- -
Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants With Relapsed, Refractory, or Newly Diagnosed Cancers
- Conditions
- Interventions
- First Posted Date
- 2020-09-17
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- IGM Biosciences, Inc.
- Target Recruit Count
- 272
- Registration Number
- NCT04553692
- Locations
- 🇺🇸
Mayo Clinic, Minneapolis, Minnesota, United States
🇺🇸Minnesota Oncology - Minneapolis Clinic, Minneapolis, Minnesota, United States
🇺🇸UCSF, San Francisco, California, United States
Birinapant and Intensity Modulated Re-Irradiation Therapy in Treating Patients With Locally Recurrent Head and Neck Squamous Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2019-01-15
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 13
- Registration Number
- NCT03803774
- Locations
- 🇺🇸
UM Sylvester Comprehensive Cancer Center at Plantation, Plantation, Florida, United States
🇺🇸University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida, United States
🇺🇸Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States
Birinapant and Carboplatin in Treating Patients With Recurrent High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-04-29
- Last Posted Date
- 2020-07-24
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Registration Number
- NCT02756130
- Locations
- 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
Dose-escalation Study of Birinapant and Pembrolizumab in Solid Tumors
- First Posted Date
- 2015-10-27
- Last Posted Date
- 2021-01-14
- Lead Sponsor
- Medivir
- Target Recruit Count
- 34
- Registration Number
- NCT02587962
- Locations
- 🇺🇸
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸The Sidney Kimmel Comprehensive Cancer Center at John Hopkins, Baltimore, Maryland, United States
🇺🇸UCLA Dept of Medicine-Hematology/Oncology, Santa Monica, California, United States
Phase I Safety and Tolerability Study of Birinapant in Chronic Hepatitis B
- Conditions
- Interventions
- First Posted Date
- 2014-11-11
- Last Posted Date
- 2016-02-05
- Lead Sponsor
- TetraLogic Pharmaceuticals
- Target Recruit Count
- 7
- Registration Number
- NCT02288208
- Locations
- 🇦🇺
Linear Clinical Research Ltd, Nedlands, Western Australia, Australia
🇦🇺CMAX / Royal Adelaide Hospital, Adelaide, South Australia, Australia
🇦🇺Nucleus Network Limited / AMREP Precinct, Melbourne, Victoria, Australia
Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL
- Conditions
- Interventions
- First Posted Date
- 2014-05-28
- Last Posted Date
- 2016-10-20
- Lead Sponsor
- TetraLogic Pharmaceuticals
- Target Recruit Count
- 118
- Registration Number
- NCT02147873
- Locations
- 🇺🇸
University of Maryland, Greenebaum Cancer Center, Baltimore, Maryland, United States
🇺🇸Desert Hematology Oncology Medical Group, Rancho Mirage, California, United States
🇺🇸Gabrail Cancer Center Research, Canton, Ohio, United States
Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-09-12
- Last Posted Date
- 2016-01-14
- Lead Sponsor
- TetraLogic Pharmaceuticals
- Target Recruit Count
- 27
- Registration Number
- NCT01940172
- Locations
- 🇺🇸
TetraLogic research site, Fresno, California, United States
🇺🇸TetraLogic Research Site, Nashville, Tennessee, United States
🇺🇸TetraLogic Research Facility, Dallas, Texas, United States
Birinapant With 5-azacitidine in MDS Subjects Who Are Naïve, Have Relapsed or Are Refractory to 5-azacitidine Therapy
- First Posted Date
- 2013-04-10
- Last Posted Date
- 2016-04-21
- Lead Sponsor
- TetraLogic Pharmaceuticals
- Target Recruit Count
- 21
- Registration Number
- NCT01828346
- Locations
- 🇺🇸
The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States
🇺🇸California Cancer Associates for Research and Excellence, Fresno, California, United States
🇺🇸Mayo Clinic Scottsdale, Scottsdale, Arizona, United States
A Phase I-II Open Label Non-Randomized Study Using TL32711 for Patients With Acute Myelogenous Leukemia, Myelodysplastic Syndrome and Acute Lymphoblastic Leukemia
- First Posted Date
- 2011-12-07
- Last Posted Date
- 2021-06-24
- Lead Sponsor
- Abramson Cancer Center at Penn Medicine
- Target Recruit Count
- 27
- Registration Number
- NCT01486784
- Locations
- 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
Dose Escalation, Combination Chemotherapy Safety Study of Birinapant (TL32711), in Subjects With Advanced or Metastatic Solid Tumors
- First Posted Date
- 2010-08-25
- Last Posted Date
- 2016-05-30
- Lead Sponsor
- TetraLogic Pharmaceuticals
- Target Recruit Count
- 176
- Registration Number
- NCT01188499
- Locations
- 🇺🇸
Barbara Ann Karmanos Cancer Center, Detroit, Michigan, United States
🇺🇸Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸Holy Cross Hospital, Fort Lauderdale, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.